| Yang, Bin |
NCT05312268: Rasburicase Treatment in Chronic Gouty Arthritis |
|
|
| Recruiting | 4 | 60 | RoW | Rasburicase | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Chronic Gout | 10/24 | 04/25 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06281561: Dexmedetomidine Premedication for Post-anaesthesia Sleep Disturbance |
|
|
| Not yet recruiting | 3 | 110 | NA | Normal Saline, Dexmedetomidine | The First Affiliated Hospital of Xiamen University | Postoperative Sleep Disturbance | 11/24 | 12/24 | | |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 2/3 | 645 | RoW | SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo | Reistone Biopharma Company Limited | Atopic Dermatitis | 09/23 | 07/24 | | |
| Recruiting | 2 | 80 | RoW | Activated CIK, CIK | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital | Advanced Liver Cancer | 01/21 | 01/21 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment |
|
|
| Recruiting | 2 | 200 | RoW | LP-003, Placebo, Omalizumab | Longbio Pharma | Chronic Spontaneous Urticaria | 01/25 | 01/25 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
| Recruiting | 2 | 159 | Europe, Canada, Japan, US, RoW | GSK1070806 | GlaxoSmithKline | Dermatitis, Atopic | 11/29 | 11/29 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 175 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 08/24 | 06/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05713110: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma |
|
|
| Recruiting | 2 | 140 | RoW | tazemetostat, HMPL-689 | Hutchmed | Relapsed/Refractory Lymphoma | 05/26 | 12/26 | | |
NCT04908046: A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Completed | 1 | 47 | RoW | HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days . | Hutchmed | Advanced Malignant Solid Tumors | 01/24 | 02/24 | | |
NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) |
|
|
| Recruiting | 1 | 10 | RoW | TQH2929 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Generalized Pustular Psoriasis | 02/25 | 02/25 | | |
NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 81 | RoW | HMPL-415S1 | Hutchmed | Advanced Malignant Solid Tumors | 05/25 | 06/26 | | |
| Not yet recruiting | N/A | 5000 | RoW | Endovascular Therapy | Chinese Academy of Medical Sciences, Fuwai Hospital | Renal Artery Obstruction, Hypertension, Renovascular | 04/22 | 04/24 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
NCT06221722: Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation |
|
|
| Recruiting | N/A | 150 | RoW | BOLD-fMRI, Regular treatment of functional constipation, fluoxetine | Xijing Hospital of Digestive Diseases | Constipation - Functional, Refractory Constipation, Fluoxetine, fMRI, Brain Connectivity, Treatment Efficacy, Somatic Symptom, Mental Symptom | 09/25 | 09/26 | | |
| Not yet recruiting | N/A | 1500 | RoW | adrenal venous sampling | Chinese Academy of Medical Sciences, Fuwai Hospital | Hyperaldosteronism | 12/26 | 12/26 | | |
| Recruiting | N/A | 320 | RoW | No intervention | The First Affiliated Hospital of Xiamen University | Rebound Pain, Arthroscopic Knee Surgery, Oliceridine | 12/25 | 12/25 | | |
NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis |
|
|
| Recruiting | N/A | 188 | RoW | Ton-bridge carotid stent, WALLSTENT carotid stent | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Carotid Artery Stenosis | 11/24 | 10/25 | | |
FLAVOUR II, NCT04397211: Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease |
|
|
| Active, not recruiting | N/A | 1872 | RoW | Angiography-derived FFR, IVUS | Second Affiliated Hospital, School of Medicine, Zhejiang University, Seoul National University Hospital, Affiliated Hangzhou First People's Hospital, Wuhan University, Peking University Third Hospital, The Affiliated Hospital of Hangzhou Normal University, RenJi Hospital, Second Hospital of Shanxi Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Changxing People's Hospital, The Affiliated Hospital of Medical College, Ningbo University, Jinhua Central Hospital, Shandong University of Traditional Chinese Medicine, Dongyang People's Hospital, The First Affiliated Hospital of Nanchang University, Jining First People's Hospital, Second Affiliated Hospital of Shantou University Medical College, Ulsan University Hospital, Huizhou Municipal Central Hospital, Zhejiang Greentown Cardiovascular Hospital, The Fourth People's Hospital of Jinan, First Affiliated Hospital of Kunming Medical University | Coronary Artery Disease | 09/24 | 09/28 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT05410652: Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method) |
|
|
| Completed | N/A | 1176 | RoW | Detection of fecal samples with diagnostic kit, Sanger Sequencing group, Bacterial culture and drug sensitivity test of gastric mucosa samples | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection, Helicobacter Pylori gyrA Levofloxacin Resistance Mutation, Fecal Drug Resistance Gene Detection, Helicobacter Pylori Infection, Susceptibility to | 09/23 | 10/23 | | |
| Wu, Lin |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06505837: JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） |
|
|
| Recruiting | 3 | 356 | RoW | Arm1: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy, Arm 2: JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer | 06/25 | 12/26 | | |
FLETEO, NCT05382728: Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 680 | RoW | TY-9591, TY-9591 Tablets, placebo Osimertinib, placebo Tagrisso, Osimertinib, Tagrisso, placebo TY-9591, placebo TY-9591 Tablets | TYK Medicines, Inc | NSCLC, EGFR Activating Mutation | 05/25 | 12/27 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 700 | RoW | HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin | Taizhou Hanzhong biomedical co. LTD | Nonsquamous Non-small Cell Lung Cancer | 09/22 | 09/23 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
NCT04740021: Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 46 | RoW | LP002, Carboplatin, Etoposide | Taizhou HoudeAoke Biomedical Co., Ltd. | Small-cell Lung Cancer | 02/22 | 08/22 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
NCT05460481: Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors |
|
|
| Recruiting | 2 | 29 | RoW | Anlotinib Plus Penpulimab, Anlotinib & Penpulimab | Hunan Cancer Hospital, Henan Cancer Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 06/23 | 12/24 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
NCT06361927: A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients |
|
|
| Recruiting | 2 | 120 | RoW | SSGJ-707 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | NSCLC | 06/25 | 07/25 | | |
| Not yet recruiting | 2 | 42 | RoW | Neratinib tablets, Epilepsy | Convalife (Shanghai) Co., Ltd. | NSCLC | 12/24 | 12/25 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |
NCT04622072: XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Terminated | 1/2 | 21 | RoW | XZP-5809-TT1 Tablet | Sihuan Pharmaceutical Holdings Group Ltd. | Non Small Cell Lung Cancer | 05/21 | 04/22 | | |
| Active, not recruiting | 1/2 | 114 | RoW | AK104+anlotinib | Akeso | NSCLC | 11/22 | 12/23 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
| Recruiting | 1/2 | 127 | RoW | TQB2618 injection and TQB2450 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT06243354: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation |
|
|
| Recruiting | 1/2 | 257 | RoW | Test product: HYP-2090PTSA | Sichuan Huiyu Pharmaceutical Co., Ltd | Safety, Tolerability, Efficacy | 12/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 354 | US, RoW | PRO1184, PRO1184 intravenous infusion of PRO1184 | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 10/25 | 04/26 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT05774873: IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 128 | RoW | IBI334 D, IBI334 C, IBI334 A, IBI334 B, IBI334 F, IBI334 E | Innovent Biologics (Suzhou) Co. Ltd. | Solid Tumors | 10/25 | 06/26 | | |
| Recruiting | 1/2 | 1000 | US, RoW | DB-1310, Trastuzumab, Osimertinib | DualityBio Inc. | Advanced Solid Tumor | 08/26 | 08/26 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT05172856: A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 110 | RoW | IBI321 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Solid Tumors | 06/23 | 12/24 | | |
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 164 | US, RoW | ABSK112, EGFR Exon20 inhibitor | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer | 03/27 | 03/28 | | |
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 156 | RoW | JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection | Shanghai Junshi Bioscience Co., Ltd. | Melanoma, Renal Carcinoma, Urothelial Carcinoma | 02/24 | 08/24 | | |
NCT06235983: A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | LY3537982, Olomorasib | Eli Lilly and Company | Advanced Solid Tumors | 01/25 | 01/26 | | |
NCT06424665: A Study of FZ-AD005 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 162 | RoW | FZ-AD005 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) | 12/25 | 06/26 | | |
NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 82 | RoW | BPI-460372 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
NCT06015568: Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation |
|
|
| Not yet recruiting | 1 | 172 | RoW | MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | 11/28 | 07/29 | | |
| Chu, Qian |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06498479: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 460 | RoW | HS-20093, Topotecan | Hansoh BioMedical R&D Company | Small Cell Lung Cancer | 09/26 | 05/27 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
ACHELOUS, NCT06001151: Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative |
|
|
| Recruiting | 2 | 49 | RoW | Cadonilimab, AK104, Pemetrexed, Carboplatin | Qian Chu, Akeso Pharmaceuticals, Inc. | Carcinoma, Non-Small-Cell Lung | 08/25 | 08/27 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
| Recruiting | 1/2 | 127 | RoW | TQB2618 injection and TQB2450 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 82 | RoW | BPI-460372 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
NCT04766515: Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms |
|
|
| Recruiting | N/A | 1500 | RoW | | Fudan University | Cancer | 08/23 | 08/25 | | |
